title: Is bisphosphonate therapy compromised by the emergence of adverse bone disorders?
abstract: Bisphosphonates (BPs) are the preferred class of antiresorptive agents used for the treatment of osteoporosis and bone metastases. Recently, an increasing number of clinical reports concerning osteonecrosis of the jaw and atypical fractures have suggested a link between prolonged use of BPs and these adverse bone events, which are exceptionally difficult to treat. Even though these side effects were mainly observed in patients with metastases, osteoporotic patients might become increasingly affected by these conditions with the increasing use of injectable BPs. Could these severe adverse bone events compromise the use of BPs? The development of these unfavorable conditions as a consequence of oversuppression of bone resorption could raise concern regarding the use of therapeutic strategies involving antiresorptive drugs.
authors: Université de Nantes, INSERM UMR 791, LIOAD, Faculté de Chirurgie Dentaire, BP 84215, 44042 Nantes Cedex 1, France. Electronic address: elise.verron@univ-nantes.fr.
authors: E
authors: E
authors: Verron
authors: Université de Nantes, INSERM UMR 791, LIOAD, Faculté de Chirurgie Dentaire, BP 84215, 44042 Nantes Cedex 1, France.
authors: J M
authors: JM
authors: Bouler
mesh_terms: D000818:Animals; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000453:epidemiology; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D050723:Fractures, Bone / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates